Interim data on long‐term efficacy, safety and tolerability of a plasma‐derived factor VIII concentrate in 109 patients with severe haemophilia A
Authors:
- 18 January 2012
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 18 (4) , 496-502
Abstract
Summary. The aim of this open‐label, multicentre and multinational post‐marketing surveillance was to investigate clinical effectiveness, safety and tolerability of a plasma‐derived and vWF containing factor VIII product (FVIII/VWF) in patients with severe haemophilia A. Long‐term effectiveness, safety and tolerability were investigated in a total of 109 haemophilia A patients treated for prophylaxis or on‐demand, as required. Interim data collected until June 2010 are presented. Most patients (99/109; 90.8%) were previously treated patients (PTPs). Mean observation period was 82.6 months. Overall, patients received 105 131 425 IU haemoctin SDH during 68 624 administrations. Each patient was given a mean of 635.4 injections, whereby about half of the administrations were given for treatment of bleeding episodes (46.9%) and the other administrations for prophylactic reasons (53.1%). Patients on prophylaxis had a median of 0.8 bleeding episodes per month. The expected therapeutic effect was reached in 99.3% of treatments. The incidence of clinically relevant inhibitor formation in patients with severe haemophilia (FVIII activity ≤ 1%) was 1.2% for PTPs. One previously untreated patient with severe haemophilia had a clinically relevant transient inhibitor. No treatment related transmissions of hepatitis A, B and C and HIV 1/2 were observed. German patients had a higher extent of exposure and experienced less bleeding episodes than Hungarian patients. In conclusion, haemoctin SDH was effective, safe and well tolerated in long‐term prophylaxis and treatment on demand.Keywords
This publication has 8 references indexed in Scilit:
- Recommendations for postmarketing surveillance studies in haemophilia and other bleeding disordersHaemophilia, 2005
- The epidemiology of inhibitors in haemophilia A: a systematic reviewHaemophilia, 2003
- Hemophilia A-From Basic Science to Clinical PracticeSeminars in Thrombosis and Hemostasis, 2002
- Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentratesHaemophilia, 1999
- Hemophilia ANew England Journal of Medicine, 1994
- A Higher than Expected Incidence of Factor VIII Inhibitors in Multitransfused Haemophilia A Patients Treated with an Intermediate Purity Pasteurized Factor VIII ConcentrateThrombosis and Haemostasis, 1993
- A More Uniform Measurement of Factor VIII InhibitorsThrombosis and Haemostasis, 1975
- Measurement of Mild Factor VIII Inhibitors in Bethesda UnitsThrombosis and Haemostasis, 1975